查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1371890

到 2030 年抗菌素抗药性诊断市场预测：按病原体、技术、最终用户和地区进行的全球分析

Antimicrobial Resistance Diagnostic Market Forecasts to 2030 - Global Analysis By Pathogen, Technology, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，2023 年全球抗菌素抗药性诊断市场规模为 47.6 亿美元，预计到 2030 年将达到 95.8 亿美元，预测期内年复合成长率为 10.5%。

用于发现和证明微生物中抗菌素抗药性（AMR）存在的诊断测试和设备市场被称为「抗菌素抗药性诊断市场」。抗生素抗药性是全世界主要的公共卫生问题，因为微生物（包括细菌、病毒、真菌和寄生虫）发展出抵抗抗生素作用的能力，导致治疗感染疾病的效果降低或消失。

根据美国药典公约，AMR 每年导致全球约 70 万人死亡。此外，如果微生物感染疾病的诊断和治疗管理不当，到2050年每年这一数字可能会达到1000万人。

配合措施和提高认识

随着医疗保健专业人员、立法者和公众对抗生素抗药性影响的了解不断加深，解决这一问题的配合措施也加大了。此外，政府、组织和法规发起了鼓励负责任地使用抗生素的运动，并开始创建和接受对抗抗药性的诊断工具。

昂贵的诊断和有限的报销政策

一些最先进的抗菌素抗药性诊断测试价格昂贵，而且其取得和使用可能受到限制，特别是在资源匮乏的地区。诊断测试的高价格可能会阻碍市场扩张，特别是在医疗资源匮乏的地区。然而，根据地区和医疗保健系统，抗菌素抗药性诊断可能会根据不同的保单得到承保和报销。特定测试的付款不足或缺乏保险可能会阻碍其普及和市场扩张。

技术开发、指南和法规遵从性

分子诊断和次世代定序等领域诊断技术的进步正在提高抗生素抗药性测试的能力。这些创新使抗药性标记物能够更快、更准确地被检测到，从而使医疗专业人员能够确定有效的治疗方法。此外，法规机构和医疗保健组织已经认识到抗生素抗药性的重要性，并发布了建议和指南来促进抗生素的使用。这些法规促进了诊断技术的普及，同时支持市场扩张所需的法规环境。

基础设施和专业知识不足，法规程序复杂

缺乏抗菌药物抗药性测试的知识可能会阻止某些地区充分发挥其潜力。医疗保健基础设施不足和缺乏检测空间也可能阻碍现代诊断技术的使用并限制市场扩张。然而，要获得法规核准新的抗生素抗药性诊断测试可能既耗时又困难。新诊断方法的推出受到严格法规的阻碍，这往往会延迟产品的发布。

COVID-19 的影响：

由于 COVID-19 大流行，医疗保健的优先事项发生了巨大变化，重点是管理和遏制病毒的传播。资源被用于 COVID-19 检测和治疗，包括实验室能力和人员。这种资源的重新分配可能暂时阻碍了对该领域抗菌素抗药性诊断和研究的关注。由于 COVID-19 患者可能继发细菌感染，因此 COVID-19 大流行导致抗生素使用增加。

预计耐甲氧西林金黄色葡萄球菌在预测期内将达到最高水平

在预测期内，抗甲氧西林金黄色葡萄球菌占据最大份额。此细分市场成长的主要原因是医院环境中耐甲氧西林金黄色葡萄球菌（MRSA）的患病不断增加。例如，美国疾病管制与预防中心 (CDC) 报告称，鼻子里有金黄色葡萄球菌的人中约有 100 人患有 MRSA。这一比例约为人口的33%。此外，影响该细分市场成长的另一个因素是越来越多的法规核准用于识别 MRSA 的诊断测试。

预计医院领域在预测期内的年复合成长率最高。

由于医院感染率上升、AMR 感染率高导致住院人数急剧增加、住院时间更长、更容易获得尖端诊断技术、负担能力以及医疗覆盖范围的改善，医院领域预计将出现下滑。在此期间实现盈利增长。此外，MRSA、CDI、DRSP等病原体感染还会引起肺炎、败血症、血流感染、手术部位感染等。因此，医院中以病原体为重点的疾病爆发也促进了这一领域的成长。

比例最高的地区：

由于抗微生物药物抗药性发展的高风险、政府对抗微生物药物抗药性的法规以及先进的医疗基础设施，北美在预测期内占据最大份额。此外，主要市场参与企业的存在和策略性倡议预计将推动未来年度的区域扩张。

复合年复合成长率最高的地区：

预计亚太地区在预测期内将出现最快的扩张。抗生素抗药性的高频率、对负担得起的诊断解决方案的需求不断增加以及开拓的市场潜力的存在正在促进该地区的成长。此外，预计该地区的扩张将受到大量目标人口、不断增长的老年人口以及众多政府资助的宣传活动的推动。此外，与创建改进的诊断解决方案相关的研发工作的成长预计将支持该地区的扩张。

免费客製化服务：

订阅此报告的客户可以存取以下免费自订选项之一：

  • 公司简介
    • 其他市场参与者的综合分析（最多 3 家公司）
    • 主要企业SWOT分析（最多3家企业）
  • 区域分割
    • 根据客户兴趣对主要国家的市场估计、预测和年复合成长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第1章执行摘要

第2章前言

  • 概述
  • 利害关係人
  • 调查范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 调查来源
    • 主要调查来源
    • 二次调查来源
    • 先决条件

第3章市场趋势分析

  • 促进因素
  • 抑制因素
  • 机会
  • 威胁
  • 技术分析
  • 最终用户分析
  • 新兴市场
  • 新型冠状病毒感染疾病（COVID-19）的影响

第4章波特五力分析

  • 供应商的议价能力
  • 买方议价能力
  • 替代的威胁
  • 新进入者的威胁
  • 竞争公司之间的敌对关係

第5章全球抗菌素抗药性诊断市场：依病原体分类

  • 抗药性链球菌
  • 抗药性肺炎链球菌 (DRSP)
  • 抗甲氧西林金黄色葡萄球菌
  • 艰难梭菌 (CD)
  • 抗药性淋病 (DRNG)
  • 抗药性沙门氏菌 (DRNTS)
  • 其他病原体

第6章全球抗菌素抗药性诊断市场：依技术分类

  • 免疫检测
  • 微生物培养
  • 质谱
  • 快速且即时护理
  • 其他技术

第7章全球抗菌素抗药性诊断市场：依最终用户分类

  • 製药和生物技术公司
  • 诊断实验室
  • 医院
  • 其他最终用户

第8章全球抗菌素抗药性诊断市场：按地区

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲

第9章进展

  • 合约、伙伴关係、协作和合资企业
  • 收购和合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第10章公司简介

  • Abbott Laboratories
  • Accelerate Diagnostics, Inc.
  • Becton, Dickinson and Company
  • Biomerieux
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Hologic, Inc.
  • Molsid
  • OpGen
  • Vela Diagnostics
  • Visby Medical, Inc.
Product Code: SMRC23947

According to Stratistics MRC, the Global Antimicrobial Resistance Diagnostic Market is accounted for $4.76 billion in 2023 and is expected to reach $9.58 billion by 2030 growing at a CAGR of 10.5% during the forecast period. The market for diagnostic tests and instruments used to find and establish the presence of antimicrobial resistance (AMR) in microorganisms is referred to as the "antimicrobial resistance diagnostic market." As a result of the development of the ability of microorganisms, including bacteria, viruses, fungi, and parasites, to withstand the effects of antimicrobial medications, which reduces or eliminates their effectiveness in treating infections, antimicrobial resistance is a major public health concern worldwide.

According to the United States Pharmacopeial Convention, AMR caused about 700,000 deaths globally every year. Moreover, the number can reach 10 million each year by 2050, if diagnosis and treatment of microbial infections are not managed properly.

Market Dynamics:

Driver:

Increasing initiatives and awareness

Increased initiatives aimed at combating the problem were made possible by the growing knowledge of the effects of antibiotic resistance among healthcare professionals, legislators, and the general public. Furthermore, governments, organizations, and regulatory authorities have started campaigns to encourage the responsible use of antibiotics as well as the creation and acceptance of diagnostic tools to combat resistance.

Restraint:

Expensive diagnostic procedures and policies for limited reimbursement

Some cutting-edge antimicrobial resistance diagnostic tests can be expensive, which restricts access to and use of them, particularly in places with low resources. The high price of diagnostic tests may be an obstacle to market expansion, especially in areas with constrained healthcare resources. However, antimicrobial resistance diagnostics may be covered and reimbursed under different policies, depending on the region and healthcare system. Their uptake and market expansion may be hampered by inadequate payment or a lack of insurance coverage for certain tests.

Opportunity:

Technological developments and guidelines and support for regulations

Diagnostic technology advancements in areas like molecular diagnostics and next-generation sequencing have improved the capability of tests for antibiotic resistance. These innovations allow for the quicker and more precise detection of resistance markers, empowering medical professionals to determine effective treatments. Additionally, the importance of antibiotic resistance has been acknowledged by regulatory bodies and healthcare organizations, which have released recommendations and guidelines to promote their usage. These regulations support the regulatory environment needed for market expansion while facilitating the uptake of diagnostics.

Threat:

Inadequate infrastructure and expertise and complex regulatory procedures

Antimicrobial resistance tests may not be used to their full potential in some areas due to a lack of knowledge about them. Inadequate healthcare infrastructure and a lack of laboratory space might also prevent the use of modern diagnostics and restrain market expansion. However, it might take a while and be difficult to get regulatory approval for novel diagnostic tests for antibiotic resistance. The introduction of novel diagnostics might be hampered by strict regulatory regulations, which can often delay the launch of products.

COVID-19 Impact:

Priorities in healthcare have dramatically changed as a result of the COVID-19 pandemic to focus on managing and containing the virus's spread. Resources have been redirected toward COVID-19 testing and treatment, including laboratory capacity and manpower. The concentration on antimicrobial resistance diagnostics and research efforts in this area may have been momentarily hampered by this resource relocation. Due to the possibility of secondary bacterial infections in COVID-19 patients, the COVID-19 pandemic has resulted in an increase in the use of antibiotics.

The methicillin resistant staphylococcus aureus segment is expected to be the largest during the forecast period

Methicillin Resistant Staphylococcus Aureus segment commanded the largest share over the forecast period. The main cause of the segment's growth is the rising prevalence of MRSA in hospital settings. For instance, the CDC reports that approximately two in every 100 of those with S. aureus on their noses develop MRSA. This percentage of the population is roughly 33%. Moreover, another element influencing the segment's growth is the rise in regulatory approvals for diagnostic tests for identifying MRSA.

The hospitals segment is expected to have the highest CAGR during the forecast period

Because of the rising rate of hospital-acquired infections, the surge in hospitalizations caused by the high rate of AMR infections, prolonged hospital stays, expanding access to cutting-edge diagnostic technologies, affordability, and better healthcare coverage, the hospital segment is predicted to grow profitably over the forecast period. Additionally, pathogenic infections, including MRSA, CDI, and DRSP, can result in pneumonia, sepsis, bloodstream infections, and surgical site infections. Therefore, the prevalence of pathogen-focused illnesses in hospitals also contributes to segment growth.

Region with largest share:

Due to the high risk of developing AMR, the presence of supportive government AMR regulations, and the region's advanced healthcare infrastructure, North America held the largest percentage over the predicted period. Furthermore, it is anticipated that regional expansion will be fueled in the upcoming years by the existence of major market participants and the strategic initiatives.

Region with highest CAGR:

During the forecast period, Asia-Pacific is expected to experience the most rapid expansion. A high frequency of antibiotic resistance, an increase in the demand for affordable diagnostic solutions, and the presence of unexplored market potential all contribute to the region's growth. Additionally, the region's expansion is also anticipated to be aided by the region's sizable, targeted population, growing geriatric population, and a number of government-sponsored awareness campaigns. Additionally, it is anticipated that growth in R&D efforts connected to the creation of improved diagnostic solutions will support region expansion.

Key players in the market:

Some of the key players in Antimicrobial Resistance Diagnostic market include: Abbott Laboratories, Accelerate Diagnostics, Inc., Becton, Dickinson and Company, Biomerieux , Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc., Molsid , OpGen, Vela Diagnostics and Visby Medical, Inc..

Key Developments:

In November 2022, Danaher Corporation came into partnership with Duke University, a research University. Under this partnership, Danaher Corporation aimed to shape Danaher Beacon for the development of Gene Therapy Innovation.

In August 2022, Becton, Dickinson, and Company entered into collaboration with Accelerate Diagnostics, Inc., a developer of rapid in-vitro diagnostics in microbiology. This Collaboration would enable the former company to help clinicians treat patients in a Constructive and organized way resulting in a decrease in costs in healthcare and helping restrict the stretch of antimicrobial resistance.

Pathogens Covered:

  • Drug Resistant Streptococcus
  • Drug Resistant Streptococcus Pneumoniae (DRSP)
  • Methicillin Resistant Staphylococcus Aureus
  • Clostridium Difficile (CD)
  • Drug Resistant Neisseria Gonorrhoeae (DRNG)
  • Drug Resistant Salmonella (DRNTS)
  • Other Pathogens

Technologies Covered:

  • Immunoassay
  • Microbiology Culture
  • Mass Spectrometry
  • Rapid & Point of Care
  • Other Technologies

End Users Covered:

  • Pharmaceutical & Biotechnology Companies
  • Diagnostic Laboratories
  • Hospitals
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Antimicrobial Resistance Diagnostic Market, By Pathogen

  • 5.1 Introduction
  • 5.2 Drug Resistant Streptococcus
  • 5.3 Drug Resistant Streptococcus Pneumoniae (DRSP)
  • 5.4 Methicillin Resistant Staphylococcus Aureus
  • 5.5 Clostridium Difficile (CD)
  • 5.6 Drug Resistant Neisseria Gonorrhoeae (DRNG)
  • 5.7 Drug Resistant Salmonella (DRNTS)
  • 5.8 Other Pathogens

6 Global Antimicrobial Resistance Diagnostic Market, By Technology

  • 6.1 Introduction
  • 6.2 Immunoassay
  • 6.3 Microbiology Culture
  • 6.4 Mass Spectrometry
  • 6.5 Rapid & Point of Care
  • 6.6 Other Technologies

7 Global Antimicrobial Resistance Diagnostic Market, By End User

  • 7.1 Introduction
  • 7.2 Pharmaceutical & Biotechnology Companies
  • 7.3 Diagnostic Laboratories
  • 7.4 Hospitals
  • 7.5 Other End Users

8 Global Antimicrobial Resistance Diagnostic Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Abbott Laboratories
  • 10.2 Accelerate Diagnostics, Inc.
  • 10.3 Becton, Dickinson and Company
  • 10.4 Biomerieux
  • 10.5 Danaher Corporation
  • 10.6 F. Hoffmann-La Roche Ltd.
  • 10.7 Hologic, Inc.
  • 10.8 Molsid
  • 10.9 OpGen
  • 10.10 Vela Diagnostics
  • 10.11 Visby Medical, Inc.

List of Tables

  • Table 1 Global Antimicrobial Resistance Diagnostic Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 3 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
  • Table 4 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
  • Table 5 Global Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
  • Table 6 Global Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
  • Table 7 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
  • Table 8 Global Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
  • Table 9 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
  • Table 10 Global Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 11 Global Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 12 Global Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
  • Table 13 Global Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 14 Global Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
  • Table 15 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 16 Global Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 17 Global Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 18 Global Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 19 Global Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 20 Global Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 21 North America Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
  • Table 22 North America Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 23 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
  • Table 24 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
  • Table 25 North America Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
  • Table 26 North America Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
  • Table 27 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
  • Table 28 North America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
  • Table 29 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
  • Table 30 North America Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 31 North America Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 32 North America Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
  • Table 33 North America Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 34 North America Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
  • Table 35 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 36 North America Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 37 North America Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 38 North America Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 39 North America Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 40 North America Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 41 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
  • Table 42 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 43 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
  • Table 44 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
  • Table 45 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
  • Table 46 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
  • Table 47 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
  • Table 48 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
  • Table 49 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
  • Table 50 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 51 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 52 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
  • Table 53 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 54 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
  • Table 55 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 56 Europe Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 57 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 58 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 59 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 60 Europe Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 61 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
  • Table 62 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 63 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
  • Table 64 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
  • Table 65 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
  • Table 66 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
  • Table 67 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
  • Table 68 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
  • Table 69 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
  • Table 70 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 71 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 72 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
  • Table 73 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 74 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
  • Table 75 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 76 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 77 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 78 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 79 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 80 Asia Pacific Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 81 South America Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
  • Table 82 South America Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 83 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
  • Table 84 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
  • Table 85 South America Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
  • Table 86 South America Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
  • Table 87 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
  • Table 88 South America Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
  • Table 89 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
  • Table 90 South America Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 91 South America Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 92 South America Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
  • Table 93 South America Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 94 South America Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
  • Table 95 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 96 South America Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 97 South America Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 98 South America Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 99 South America Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 100 South America Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 101 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Country (2021-2030) ($MN)
  • Table 102 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Pathogen (2021-2030) ($MN)
  • Table 103 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus (2021-2030) ($MN)
  • Table 104 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Streptococcus Pneumoniae (DRSP) (2021-2030) ($MN)
  • Table 105 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Methicillin Resistant Staphylococcus Aureus (2021-2030) ($MN)
  • Table 106 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Clostridium Difficile (CD) (2021-2030) ($MN)
  • Table 107 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Neisseria Gonorrhoeae (DRNG) (2021-2030) ($MN)
  • Table 108 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Drug Resistant Salmonella (DRNTS) (2021-2030) ($MN)
  • Table 109 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other Pathogens (2021-2030) ($MN)
  • Table 110 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Technology (2021-2030) ($MN)
  • Table 111 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Immunoassay (2021-2030) ($MN)
  • Table 112 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Microbiology Culture (2021-2030) ($MN)
  • Table 113 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Mass Spectrometry (2021-2030) ($MN)
  • Table 114 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Rapid & Point of Care (2021-2030) ($MN)
  • Table 115 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other Technologies (2021-2030) ($MN)
  • Table 116 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By End User (2021-2030) ($MN)
  • Table 117 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Pharmaceutical & Biotechnology Companies (2021-2030) ($MN)
  • Table 118 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Diagnostic Laboratories (2021-2030) ($MN)
  • Table 119 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 120 Middle East & Africa Antimicrobial Resistance Diagnostic Market Outlook, By Other End Users (2021-2030) ($MN)